secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK:        0000879407
Form:       8-K
Filed at:   2023-05-02T23:59:59+00:00
Accession:  0001628280-23-014859
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arrowhead Q2 net income $48.7M ($0.45 diluted); milestones from Takeda, GSK, positive ARO-RAGE data
--------------------------------------------------------------------------------

- Revenue $146.3M, operating income $48.2M, net income $48.7M ($0.45 diluted), up from $44.4M ($0.41) in prior year.
- Earned $40M milestone from Takeda for fazirsiran Phase 3 start; $30M from GSK for Phase 2b of GSK4532990 (NASH).
- Phase 1/2 ARO-RAGE: mean max 80% reduction in serum sRAGE after two 92 mg doses; no serious AEs; supports lung delivery platform.
- Regained rights to ARO-PNPLA3 from Janssen; FDA Fast Track for ARO-APOC3 for familial chylomicronemia syndrome.
- Cash and investments $559.8M vs $482.3M at Sept 30, 2022; R&D Day June 1, 2023; ARO-SOD1 on track for Q3 CT filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879407/000162828023014859/0001628280-23-014859-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879407/000162828023014859/arwr-20230502.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-014859

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer